Ranbaxy Daiichi Sankyo

Singh brothers get 6-month jail term in Fortis-Daiichi Sankyo case

Former Ranbaxy promoters Malvinder Singh and Shivinder Singh are accused of concealing information about wrongdoing at Ranbaxy during its sale of a majority stake to Daiichi Sanyo, in 2008

What brought down the Ranbaxy-Fortis promoters?

Ranbaxy promoters Malvinder and Shivinder Singh have been in the news for wrong reasons. The latest development is one more chapter in the story of their downfall. Here's a peek into their journey

SC holds Malvinder, Shivinder guilty of contempt in Daiichi Sankyo case

Daiichi Sankyo has alleged the brothers created encumbrances on 1.2 million shares of Fortis in violation of court orders

Religare fraud: What led to Singh brothers' arrest in the Rs 2,400-cr case

The police also arrested former Religare Finvest MD Kavi Arora, and former Religare Group CFO Anil Saxena along with former Religare MD Sunil Godhwani

How the Daiichi CEO capped a $37 billion recovery with a cancer drug deal

The stock was in the middle of a six-year free fall, its Indian subsidiary Ranbaxy Laboratories Ltd. was banned by the US from selling products there

Daiichi-Ranbaxy row: HC asks Singh brothers to divulge foreign bank details

The court listed the matter for further hearing on September 25

Delhi HC restricts former Ranbaxy promoters from selling assets

The Delhi High Court on Monday ordered former Ranbaxy promoters Malvinder Singh and Shivinder Singh not to part with any unencumbered (charge-free) assets without first approaching the court in a bid to secure funds for a Rs 2,562 crore Singapore arbitration award in favour of Japanese pharma major Daiichi Sankyo.Senior advocates C A Sundaram and Arvind Nigam, appearing on behalf of Daiichi, began the day's proceedings by pressing on an application seeking to restrain the Singh brothers from transferring shares in subsidiary companies of RHC Holdings (the holding company for a majority of the former Ranbaxy promoters' assets). The application followed two previous attempts to stop the possible sale of Fortis Healthcare, which the Singh brothers have claimed is only to infuse capital into the enterprise and represents 5-10 percent of their encumbered asset value. The Daiichi counsels also informed the court that the Singh brothers had failed to submit all details of their unencumbered .

Ranbaxy-Daiichi affair: How & why the deal went south

As far back as 2004, Ranbaxy was well aware of the possible repercussions of its alleged improper regulatory filings

Rs 3,500-cr fine on Singh bros, not Rs 2,562 cr: Daiichi

The judgment was pronounced by an arbitration court in Singapore on April 29